| Document |
Document Title |
|
WO/2023/235384A1 |
Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of enhancing readthrough of genes containing premature termina...
|
|
WO/2023/232560A1 |
The present invention relates to a process for the preparation of a compound of formula (II) wherein M is selected among Na, K and Li, by reacting a compound of formula (I) wherein R1 is selected among hydrogen, Na, K and Li, with a base...
|
|
WO/2023/227737A1 |
The present invention relates to compounds of Formula (I), (I) or an agronomically acceptable salt of said compounds wherein A1, A2, A3, X1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. The invention further relates to herbicidal...
|
|
WO/2023/227676A1 |
The present invention relates to the use of malonic acid monoamides and malonamide esters of the formula (I) wherein the variables are as defined in the claims and the description, for controlling unwanted vegetation, to a method for com...
|
|
WO/2023/225327A1 |
Compounds, compositions, and methods for making and using the compounds for treatment of cancer are provided herein. Mechanistically, these compounds were found to bind to RPS23 and were effective in activating the inducible stress respo...
|
|
WO/2023/221868A1 |
Provided in the present invention are a derivative of an isoxazoline compound and the use thereof in the prevention and treatment of parasitic infections. The derivative of the isoxazoline compound has the following general structural fo...
|
|
WO/2023/221862A1 |
Provided are an anti-parasitic infection external pharmaceutical formulation , a preparation method therefor and use thereof. The external pharmaceutical formulation comprises a first active ingredient and an aldehyde compound, the first...
|
|
WO/2023/222850A1 |
The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
|
|
WO/2023/194496A1 |
A process for the preparation of compound of formula (I) is provided: where R, R1, R2, R3 and R4 are as defined in the description.
|
|
WO/2023/182871A1 |
The present invention relates to a 3-phenylisoxazole derivative, a preparation method therefor, and a pharmaceutical composition for preventing or treating eye disease, containing same as an active ingredient. The 3-phenylisoxazole deriv...
|
|
WO/2023/170025A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are amido cyclopropyl derivatives, methods of preparing such compo...
|
|
WO/2023/158602A1 |
Disclosed are compounds of Formula I including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein G, Z, L, J, A and T are as defined in the disclosure. Also disclosed are compositions containing the compound...
|
|
WO/2023/155912A1 |
The present invention provides a recyclable hypervalent iodine reagent having a high reactivity. Specifically, the invention provides a hypervalent iodine reagent capable of realizing high-selectivity coupling, and a method for preparing...
|
|
WO/2023/157862A1 |
Provided is a method for producing α-fluoroether starting from an inactivated chloride. Disclosed is a method for producing a compound represented by formula (3), the method comprising step A in which a compound represented by formula (...
|
|
WO/2023/154466A1 |
Arylbenzoisoxazole compounds of Formula (II), where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcohol...
|
|
WO/2023/152415A1 |
The present invention relates to a compound of formula I, wherein the groups R1 to R5 and Cy have the meaning described in the description, for use thereof in the treatment and/or prevention of an infection or disease caused by the infec...
|
|
WO/2023/115165A1 |
The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
|
|
WO/2023/114824A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/114818A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/114819A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/104616A1 |
The invention relates to a novel method for producing isoxazolinecarboxylic acid derivatives of formula (I).
|
|
WO/2023/104035A1 |
Disclosed are a substituted monocyclic or bicyclic heterocyclic compound, a preparation method therefor and a medical use thereof. Specifically, disclosed are a substituted monocyclic or bicyclic heterocyclic compound having a structure ...
|
|
WO/2023/097809A1 |
The present invention relates to the technical field of fireproof flame-retardant coatings. An antibacterial fireproof coating based on a sulfanilamide-silver chemical compound and a preparation method thereof. The preparation method of ...
|
|
WO/2023/101595A1 |
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and bin...
|
|
WO/2023/099641A1 |
The present invention relates to a new process for producing isoxazoline-5,5-vinylcarboxylic acid derivatives of formula (I).
|
|
WO/2023/092219A1 |
There is provided adjunctive D-cycloserine (DCS) augmentation of transcranial magnetic stimulation (TMS) therapy for Obsessive Compulsive Disorder (OCD). There is also provided combination therapies and therapeutic methods that include i...
|
|
WO/2023/096304A1 |
The present invention relates to an isoxazole derivative or a pharmaceutically acceptable salt thereof and a composition for preventing or treating CSF-1R related diseases comprising the derivative as an active ingredient. The isoxazole ...
|
|
WO/2023/090859A1 |
The present invention relates to: a novel method for preparing an isoxazole derivative, which is useful as a farnesoid X receptor (FXR, NR1H4) agonist; a novel intermediate used in the preparation method; and a method for preparing the p...
|
|
WO/2023/090858A1 |
The present invention relates to: a novel method for preparing an isoxazole derivative that is useful as an agonist for a farnesoid X receptor (FXR, NR1H4) and an intermediate for preparing the agonist; and a method for preparing an inte...
|
|
WO/2023/072671A1 |
The present invention relates to the use of strobilurin type compounds of formula I and the N- oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b...
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/073115A1 |
The present invention relates to the use of the compound of the formula (I) and the composition thereof as control agent for plant diseases caused by fungi, oomycetes and bacteria. Plant pathogens produce self-aggregating proteins, like ...
|
|
WO/2023/060811A1 |
Disclosed in the present invention are a fluralaner intermediate and a method for preparing fluralaner thereby. The fluralaner intermediate-5 is aaa. A synthetic route comprises: using m-xylene as a starting raw material, performing halo...
|
|
WO/2023/054702A1 |
The present invention addresses the problem of providing an industrially preferable method for producing an aldehyde represented by formula (3) or (4): (3) (4). The present invention produces a compound of formula (3) or compound of fo...
|
|
WO/2023/047416A1 |
The present invention relates to a novel process for preparation of an isoxazole compound of formula (I) by reacting a compound of formula (II) with a compound of formula (III). wherein, n is 0, 1 or 2; 10 R1, R2, R3 and R4 are independe...
|
|
WO/2023/031061A1 |
The present invention relates to a process for the preparation of a compound of formula (I) or an enriched composition comprising a compound of formula (I), by reacting a compound of formula (II),with hydroxylamine or its salt, a base, a...
|
|
WO/2023/031199A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of the s...
|
|
WO/2023/025277A1 |
Provided are an aromatic ring-containing biological antagonist as represented by general formula (I) or a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the prepa...
|
|
WO/2023/028074A1 |
Disclosed are 4-hydroxylphenyl substituted carbocycles and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat d...
|
|
WO/2023/020274A1 |
The present invention belongs to the technical field of pesticides; and specifically relates to a 3-isoxazolidinone compound and a preparation method therefor, and a herbicidal composition and the use thereof. The 3-isoxazolidinone compo...
|
|
WO/2023/023242A1 |
Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N- oxides, and salts thereof, wherein Q1, Q2 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 an...
|
|
WO/2023/015395A1 |
Provided are beneficial and therapeutic Amanita muscaria compositions. In some embodiments, the provided /L muscaria compositions comprise A. muscaria extracts. In some embodiments, the provided A muscaria compositions comprise one or mo...
|
|
WO/2023/010203A1 |
This invention relates to the extraction of psychoactive compounds from psychedelic organisms for use in medicine. Raw psychedelic organisms are dried and pulverized. The psychoactive compounds are extracted using a solvent to result in ...
|
|
WO/2023/012821A1 |
The present invention provides a process for the preparation of a compound of Formula I, wherein, # indicates the attachment to isoxazoline ring and * indicates the attachment to the carbonyl carbon, The present invention particularly pr...
|
|
WO/2023/007188A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or pol...
|
|
WO/2023/007429A1 |
The present invention discloses a process for the preparation of phenyl sulfilimines or sulfoximines containing thiazolyl-piperidinyl compounds of formula (I) wherein, R1, R2, Ra, Q, n and m are as defined in the description, and interme...
|
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
|
WO/2023/283453A1 |
The disclosure herein provides phenyl acetamide based compounds of Formula (I), (I-a), (II), and pharmaceutical compositions thereof, for the modulation of IL-17A, useful in the treatment of inflammatory conditions such as psoriasis.
|
|
WO/2023/274870A1 |
The invention relates to a novel method for producing isoxazolinecarboxylic acid derivatives of formula (I).
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
